Intravenous Immunoglobulin Therapy Administered Early after Narcolepsy Type 1 Onset in Three Patients Evaluated by Clinical and Polysomnographic Follow-Up
Table 1
Clinical and MSLT characteristics at baseline and under IVIg therapy.
Evaluation
Patient number 1—IVIg 1 month after cataplexy onset
Patient number 2—IVIg 2 months after cataplexy onset
Patient number 3—IVIg 4 months after cataplexy onset
Baseline
1 month
2 months
3 months
6 months of medication
Baseline
1 month
2 months
3 months
6 months of medication
Baseline
1 month
2 months
3 months
6 months of medication
Generalized cataplexy
>5/day
≤2/day
2/week
2/week
3/week
>5/day
≤3/day
>5/day
>5/day
>5/day
<1/day
<1/week
<1/week
<1/week
0
Naps
≤3/day
1/day
1/day
1/day
0
5-6/day
5-6/day
5-6/day
5-6/day
1-2/day
2/day
≤2/day
≤2/day
≤2/day
1/day
MSLT
5.8 min
1.6 min
2.1 min
2 min
NA
3.8 min
3.2 min
1.2 min
0.7 min
NA
8 min
2.9 min
2.6 min
9.2 min
NA
3 SOREM
3 SOREM
3 SOREM
4 SOREM
4 SOREM
5 SOREM
5 SOREM
4 SOREM
2 SOREM
3 SOREM
5 SOREM
5 SOREM
Clinical follow-up at 6 months was done under daily medication with modafinil 400 mg and clomipramine 10 mg; modafinil 600 mg and clomipramine 50 mg; and modafinil 400 mg and sodium oxybate 5 g. NA: no available data.
